Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Lindsay N BargerDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-8939-092X
Derek WangCenter for Computational and Integrative Biology (CCIB), Rutgers University, Camden, New Jersey.ORCID 0009-0000-2542-6030
Ashley L SaraviaDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0004-5815-3146
Valeria MezzanoDepartment of Pathology, New York University Langone Medical Center, New York, New York.ORCID 0000-0003-4675-9146
Gyles WardExperimental Pathology, Division of Advanced Research Technologies, New York University Langone Medical Center, New York, New York.ORCID 0000-0002-3129-2523
Cynthia LoomisDepartment of Pathology, New York University Langone Medical Center, New York, New York.ORCID 0000-0001-8668-1270
Carly FeldmanDepartment of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.ORCID 0009-0005-4935-7646
Madalina TulucDepartment of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.ORCID 0000-0003-4920-3901
Rino S SeedorImmune Cell Regulation and Targeting Program, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0002-8494-3289
Peter J GaskillDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0003-0095-5424
Anna E CoghillCancer Epidemiology Program, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0001-7142-7499
Gita SunejaDepartment of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0002-5933-211X
Iman DehzangiCenter for Computational and Integrative Biology (CCIB), Rutgers University, Camden, New Jersey.ORCID 0000-0001-8577-0271
Jennifer L HopeImmune Cell Regulation and Targeting Program, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0002-2363-5442
George JourDepartment of Pathology, New York University Langone Medical Center, New York, New York.ORCID 0000-0001-8916-8966
Gabriele RomanoDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-8023-8657
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
Viral Gene Editing and Bioinformatics Core for Institution # 269291P30MH092177 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Ilker Kudret Sariyer · 2011 to 2026
$24.9M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
Benzodiazepine mediated mechanisms of transcriptional semi-quiescence in discrete myeloid populationsR01DA057337 · NIDA · DREXEL UNIVERSITY · PI Peter Jesse Gaskill, Zachary Alan Klase · 2022 to 2026
$3.4M
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIVR33DA058501 · NIDA · DREXEL UNIVERSITY · PI Peter Jesse Gaskill · 2025 to 2026
$1.4M
Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIVR61DA058501 · NIDA · DREXEL UNIVERSITY · PI GASKILL, PETER JESSE · 2023 to 2024
$1.1M
Multispectral imaging & analysis of intact tissue sections w/ the Perkin Elmer VectraS10OD021747 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOOMIS, CYNTHIA A · 2016 to 2016
$359k
American Cancer Society (ACS) DBG-23-1036360-01Congressionally Directed Medical Research Programs (CDMRP) ME220048National Cancer Institute (NCI) P30CA016087National Cancer Institute (NCI) S10-OD021747National Institute of Mental Health (NIMH) P30MH092177National Institute of Mental Health (NIMH) T32-MH079785National Institute on Drug Abuse (NIDA) DA057337National Institute on Drug Abuse (NIDA) DA058051NCI NIH HHS P30 CA016087NIDA NIH HHS R01 DA057337NIDA NIH HHS R33 DA058501NIDA NIH HHS R61 DA058501NIH HHS S10 OD021747NIMH NIH HHS P30 MH092177NIMH NIH HHS T32 MH079785Sidney Kimmel Medical College, Thomas Jefferson University (SKMC) 00023568Sidney Kimmel Medical College, Thomas Jefferson University (SKMC) 901333W. W. Smith Charitable Trust (WWSCT) C2303
6 · The paper itself
Abstract
purposeTo dissect the clinical and immunologic features of people living with human immunodeficiency virus (HIV; PLWH) diagnosed with melanoma, who have consistently shown worse outcomes than HIV-negative individuals (PLw/oH) with the same cancer. EXPERIMENTAL
designWe analyzed electronic health records from 1,087 PLWH and 394,437 PLw/oH with melanoma. Demographic and clinical characteristics were compared. Spatial immune transcriptomics (72 immune-related genes) was performed on melanoma tumor samples (n = 11), with downstream validation using multiplex immunofluorescence (mIF; n = 15 PLWH, n = 14 PLw/oH).
resultsPLWH were diagnosed at a younger age, had a greater representation of Hispanic and Black individuals, and showed reduced survival. They also had a markedly increased risk of brain metastases. PLWH experienced significant delays in initiating immune checkpoint inhibitor (ICI) therapy and had worse post-ICI survival, even after balancing covariates. Spatial transcriptomics revealed a more immunosuppressive tumor microenvironment in PLWH, with increased transcription of immune checkpoints (PD-1, LAG3) and reduced antigen-presentation markers (HLA-DRB, B2M), along with distinct spatial distributions in tumors and surrounding microenvironments. mIF demonstrated features of an exhausted CD8+ T-cell compartment, including enrichment of PD-1intLAG3- and PD-1intLAG3+ subpopulations and a significant accumulation of myeloid-derived suppressor cells (MDSC; CD11b+ HLA-DR- CD33+).
conclusionsMelanoma in PLWH is associated with distinct clinical and immunologic features, including delayed ICI treatment, reduced survival, and an immunosuppressive microenvironment with exhausted CD8+ T cells and expanded MDSCs. These findings suggest that chronic HIV infection may impair antitumor immunity in melanoma. Targeting the pathways identified here may improve therapeutic responses and outcomes in this population.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV. · full record | OpenQuestion